Dische S, Saunders M I, Dunphy E P, Bennett M H, Des Rochers C, Stratford M R, Minchinton A I, Orchard R A
Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1109-11. doi: 10.1016/0360-3016(86)90237-3.
Misonidazole, SR-2508 and Ro 03-8799 have been given in sequence to patients before tumor sampling. Tumor concentrations of the three drugs have been measured and it has been possible to make prediction as to the likely advantage of the newer drugs over misonidazole. Based upon the three cases described here and 13 others given two drug combination, we suggest that in multifraction radiotherapy, both are likely to prove more than five times more efficient than misonidazole.
在对患者进行肿瘤采样前，已按顺序给予其灭滴灵、SR - 2508和Ro 03 - 8799。已测量了这三种药物在肿瘤中的浓度，并且能够预测新药相对于灭滴灵可能具有的优势。基于此处描述的3例病例以及其他13例接受两种药物联合治疗的病例，我们认为在多分割放射治疗中，这两种新药可能比灭滴灵有效五倍以上。
